|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00000568 |
Purpose
In the Lung Health Study I, to determine the effects of Special Care, compared to Usual Care, on rate of decline in pulmonary function in a group of cigarette smokers identified as having mild abnormalities in pulmonary function.
In the Lung Health Study III, to determine the long-term effects of smoking cessation and continued smoking, on cardiopulmonary morbidity, mortality, and the rate of decline in the one second forced expiratory volume (FEV1) in men and women with early chronic obstructive lung disease who have been followed prospectively for 12 to 15 years.
| Condition | Intervention | Phase |
|
Lung Diseases Lung Diseases, Obstructive Chronic Obstructive Pulmonary Disease |
Behavioral: smoking cessation Drug: ipratropium |
Phase III |
| MedlinePlus related topics: | COPD (Chronic Obstructive Pulmonary Disease) Quitting Smoking Smoking |
| Drug Information available for: | Ipratropium Ipratropium bromide |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double-Blind, Placebo Control |
| Study Start Date: | September 1984 |
| Estimated Study Completion Date: | January 2005 |
![]() |
Show Detailed Description |
Eligibility
| Ages Eligible for Study: | 35 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Men and women who were cigarette smokers and between the ages of 35 and 60.
Contacts and Locations
More Information
| Study ID Numbers: | 206 |
| First Received: | October 27, 1999 |
| Last Updated: | August 17, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000568 |
| Health Authority: | United States: Federal Government |
|
|
|